January 24th, Vice-Governor of St. Petersburg, Igor Golikov visited
the special economic zone "Saint-Petersburg", the "Neudorf" area. The
delegation included also the Chairman of the Committee for Industrial
Policy and Innovation, Maxim Meyksin, and Head of the Area Development
and Projects Maintenance, Vladimir Smirnov.
A special tour of the R&D Center of the Company "Geropharm" (JSC
"Farm Holding") was organized for the guests. During the tour they
attended high-tech premises of the Research Center - laboratory for the
substances synthesis, analytical laboratoy and laboratories for
development of finished dosage forms.
The own R&D Center of the company was opened in December 2011 as
part of a pharmaceutical cluster in the special economic zone "Neudorf".
The Research center specializes in drug development on the full cycle
principle: from the synthesis of molecules to the development of
finished dosage form, it also organizes pre-clinical and clinical
Areas of Research are neurology, ophthalmology, hepatology, urology,
gynecology, endocrinology, serious cardiovascular disorders. The R&D
Center fully satisfies internationally accepted standards of Good
Laboratory Practice GLP (Good Laboratory Practice) and has the advanced
equipment. In the near future the company is planning to increase the
area of the R&D center by establishing new and expanding existing
The particular interest of the vice-governor was drawn to the
development degree of insulin and medicines participating in the federal
target program "Development of the Pharmaceutical and Medical Industry
of the Russian Federation for the Period up to 2020 and beyond".
Director of the R&D Center, Oleg Granstrem, spoke about the
production area of the company in Obolensk city. The new plant, which
will be opened in 2013, will produce modern pharmaceuticals for the
treatment of diabetes and other socially-significant diseases.
JSC "Geropharm-Bio" (formerly "National Biotechnology") is Russia's first commercial full-cycle producer of recombinant human insulin. Today the capacity of the company allows providing 20% of the country's need for insulin. A key aspect here is the strategically-independent production from foreign suppliers.